Atlas Trials

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

Clinical trial NCT05289856 · UNKNOWN

Trial details

NCT number
NCT05289856
Sponsor
Johannes Gutenberg University Mainz
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Cancer
Start date
2022-03-28
Primary completion
2025-03-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.